You have 9 free searches left this month | for more free features.

in combination with pembrolizumab

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cervical Cancer Trial in Miami (Pembrolizumab, Paclitaxel, Cisplatin)

Recruiting
  • Cervical Cancer
  • Miami, Florida
    University of Miami
Oct 1, 2022

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,

Not yet recruiting
  • Cervical Cancer
  • +2 more
  • PRGN-2009 plus Pembrolizumab
  • Pembrolizumab alone
  • Bethesda, Maryland
    National Institute of Health
Nov 27, 2023

Gastric Cancer, GastroEsophageal Cancer Trial in Aurora, Colorado Springs, Highlands Ranch (Pembrolizumab, Olaparib,

Recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Aurora, Colorado
  • +2 more
Jan 4, 2023

MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Aug 17, 2023

Advanced Solid Tumors Trial (AMG 355, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Nov 9, 2023

GastroEsophageal Cancer, Gastric Cancer Trial in Tampa (Neratinib, Trastuzumab, Oxaliplatin)

Recruiting
  • GastroEsophageal Cancer
  • Gastric Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Oct 25, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)

Not yet recruiting
  • Urothelial Carcinoma
  • Naptumomab Estafenatox
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023

Advanced Solid Tumor Trial (FB849, FB849 Monotherapy, FB849 in Combination with Pembrolizumab (Type A cancer))

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Feb 27, 2023

Solid Tumors Trial in Charlottesville (XmAb662, Keytruda® (pembrolizumab))

Recruiting
  • Solid Tumors
  • XmAb662
  • Keytruda® (pembrolizumab)
  • Charlottesville, Virginia
    University Of Virginia Comprehensive Cancer Center
Aug 10, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Biliary Tract Cancer Trial (GEN-001, Pembrolizumab, mFOLFOX)

Not yet recruiting
  • Biliary Tract Cancer
  • (no location specified)
Aug 16, 2023

Gastric Cancer Stage IIIB-IIIC Trial in Shanghai (Pembrolizumab + SOX)

Recruiting
  • Gastric Cancer Stage IIIB-IIIC
  • Pembrolizumab + SOX
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 7, 2023

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Recurrent Vulvar Cancer
  • +3 more
  • (no location specified)
Jun 12, 2023

Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue Trial in Warsaw (Pembrolizumab, Eftilagimod alpha)

Recruiting
  • Neoadjuvant
  • +3 more
  • Pembrolizumab, Eftilagimod alpha
  • Warsaw, Poland
    Maria Sklodowska-Curie National Research Institute of Oncology
Nov 7, 2023

Advanced Solid Tumor, Metastatic Solid Tumor Trial in Nashville, Dallas, Fairfax (JZP898, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Nashville, Tennessee
  • +2 more
Oct 26, 2023

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Jun 26, 2023

Lung Cancer Trial (TILT-123, Pembrolizumab)

Not yet recruiting
  • Lung Cancer
  • TILT-123
  • Pembrolizumab
  • (no location specified)
Nov 5, 2023

Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover

Not yet recruiting
  • Metastatic Melanoma
  • +2 more
  • Lifileucel plus Pembrolizumab
  • Pembrolizumab with Optional Crossover Period
  • (no location specified)
Feb 13, 2023

Solid Tumor Trial (SKB264, Pembrolizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Dec 8, 2022

Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma Trial (XNW5004, Pembrolizumab 25 mg/mL Solution for

Not yet recruiting
  • Carcinoma
  • +7 more
  • XNW5004
  • Pembrolizumab 25 mg/mL Solution for Injection
  • (no location specified)
Aug 31, 2023

Solid Tumor Trial in San Antonio, Tyler, Spokane (TU2218 + Pembrolizumab)

Recruiting
  • Solid Tumor
  • TU2218 + Pembrolizumab
  • San Antonio, Texas
  • +2 more
Mar 26, 2023